Cargando…

CE–MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer

BACKGROUND: Prostate cancer progresses slowly when present in low risk forms but can be lethal when it progresses to metastatic disease. A non-invasive test that can detect significant prostate cancer is needed to guide patient management. METHODS: Capillary electrophoresis/mass spectrometry has bee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frantzi, Maria, Gomez Gomez, Enrique, Blanca Pedregosa, Ana, Valero Rosa, José, Latosinska, Agnieszka, Culig, Zoran, Merseburger, Axel S., Luque, Raul M., Requena Tapia, María José, Mischak, Harald, Carrasco Valiente, Julia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738044/ https://www.ncbi.nlm.nih.gov/pubmed/31092909 http://dx.doi.org/10.1038/s41416-019-0472-z

Ejemplares similares

Validation of diagnostic nomograms based on CE–MS urinary biomarkers to detect clinically significant prostate cancer
por: Frantzi, Maria, et al.
Publicado: (2022)

Mass Spectrometry-Based Biomarkers to Detect Prostate Cancer: A Multicentric Study Based on Non-Invasive Urine Collection without Prior Digital Rectal Examination
por: Frantzi, Maria, et al.
Publicado: (2023)

Urinary CE-MS peptide marker pattern for detection of solid tumors
por: Belczacka, Iwona, et al.
Publicado: (2018)

Author Correction: Urinary CE-MS peptide marker pattern for detection of solid tumors
por: Belczacka, Iwona, et al.
Publicado: (2019)

Clinical association of metabolic syndrome, C‐reactive protein and testosterone levels with clinically significant prostate cancer
por: Gómez‐Gómez, Enrique, et al.
Publicado: (2018)

Promise and Implementation of Proteomic Prostate Cancer Biomarkers
por: Latosinska, Agnieszka, et al.
Publicado: (2018)

Plasma ghrelin O‐acyltransferase (GOAT) enzyme levels: A novel non‐invasive diagnosis tool for patients with significant prostate cancer
por: Gómez‐Gómez, Enrique, et al.
Publicado: (2018)

Omics Derived Biomarkers and Novel Drug Targets for Improved Intervention in Advanced Prostate Cancer
por: Frantzi, Maria, et al.
Publicado: (2020)

Telomere-based risk models for the early diagnosis of clinically significant prostate cancer
por: Rubio Galisteo, Juan Manuel, et al.
Publicado: (2020)

Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA <10 ng/mL
por: Gomez Gomez, Enrique, et al.
Publicado: (2019)

Reproducibility Evaluation of Urinary Peptide Detection Using CE-MS
por: Mavrogeorgis, Emmanouil, et al.
Publicado: (2021)

A Model to Detect Significant Prostate Cancer Integrating Urinary Peptide and Extracellular Vesicle RNA Data
por: O’Connell, Shea P., et al.
Publicado: (2022)

Integrative analysis of extracellular and intracellular bladder cancer cell line proteome with transcriptome: improving coverage and validity of –omics findings
por: Latosinska, Agnieszka, et al.
Publicado: (2016)

Does Adding Standard Systematic Biopsy to Targeted Prostate Biopsy in PI-RADS 3 to 5 Lesions Enhance the Detection of Clinically Significant Prostate Cancer? Should All Patients with PI-RADS 3 Undergo Targeted Biopsy?
por: Gomez-Gomez, Enrique, et al.
Publicado: (2021)

Molecular Changes in Tissue Proteome during Prostate Cancer Development: Proof-of-Principle Investigation
por: Latosinska, Agnieszka, et al.
Publicado: (2020)

Clinical proteomic biomarkers: relevant issues on study design & technical considerations in biomarker development
por: Frantzi, Maria, et al.
Publicado: (2014)

Palliative Surgery for Rare Cases of Anterior Urethral Metastasis in Prostate Cancer
por: Gómez Gómez, Enrique, et al.
Publicado: (2014)

Proteomics analysis of bladder cancer invasion: Targeting EIF3D for therapeutic intervention
por: Latosinska, Agnieszka, et al.
Publicado: (2017)

A Novel Pipeline for Drug Repurposing for Bladder Cancer Based on Patients’ Omics Signatures
por: Mokou, Marika, et al.
Publicado: (2020)

Bile and urine peptide marker profiles: access keys to molecular pathways and biological processes in cholangiocarcinoma
por: Voigtländer, Torsten, et al.
Publicado: (2020)

Role of Multiparametric Prostate Magnetic Resonance Imaging before Confirmatory Biopsy in Assessing the Risk of Prostate Cancer Progression during Active Surveillance
por: Salguero, Joseba, et al.
Publicado: (2021)

Prostate Cancer Patients–Negative Biopsy Controls Discrimination by Untargeted Metabolomics Analysis of Urine by LC-QTOF: Upstream Information on Other Omics
por: Fernández-Peralbo, M. A., et al.
Publicado: (2016)

Silencing of Profilin-1 suppresses cell adhesion and tumor growth via predicted alterations in integrin and Ca(2+) signaling in T24M-based bladder cancer models
por: Frantzi, Maria, et al.
Publicado: (2016)

The mRNA related ceRNA–ceRNA landscape and significance across 20 major cancer types
por: Xu, Juan, et al.
Publicado: (2015)

Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Cancer
por: Gómez-Gómez, Enrique, et al.
Publicado: (2019)

Significance of Affection Changes during Pregnancy: Intimacy, Passion, and Commitment
por: Fernández-Carrasco, Francisco Javier, et al.
Publicado: (2019)

Construction of a ceRNA network in glioma and analysis of its clinical significance
por: Liu, Guangdong, et al.
Publicado: (2021)

Comparative Analysis of Label-Free and 8-Plex iTRAQ Approach for Quantitative Tissue Proteomic Analysis
por: Latosinska, Agnieszka, et al.
Publicado: (2015)

Artificial neural network identified the significant genes to distinguish Idiopathic pulmonary fibrosis
por: Li, Zhongzheng, et al.
Publicado: (2023)

Preoperative chemoradiotherapy in rectal cancer induces changes in the expression of nuclear β-catenin: prognostic significance
por: Gomez-Millan, Jaime, et al.
Publicado: (2014)

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer
por: Culig, Zoran
Publicado: (2017)

Response to Androgens and Androgen Receptor Antagonists in the Presence of Cytokines in Prostate Cancer
por: Culig, Zoran
Publicado: (2021)

Identification of rare alternative splicing events in MS/MS data reveals a significant fraction of alternative translation initiation sites
por: Kroll, José E., et al.
Publicado: (2014)

Clinical Utility of Ghrelin-O-Acyltransferase (GOAT) Enzyme as a Diagnostic Tool and Potential Therapeutic Target in Prostate Cancer
por: Jiménez-Vacas, Juan M., et al.
Publicado: (2019)

T1 bladder carcinoma with variant histology: pathological features and clinical significance
por: Lopez-Beltran, Antonio, et al.
Publicado: (2022)

Significance of Vestibular Testing on Distinguishing the Nerve of Origin for Vestibular Schwannoma and Predicting the Preservation of Hearing
por: He, Yu-Bo, et al.
Publicado: (2016)

CFM-ID 3.0: Significantly Improved ESI-MS/MS Prediction and Compound Identification
por: Djoumbou-Feunang, Yannick, et al.
Publicado: (2019)

Investigation of Twelve Significant Mycotoxin Contamination in Nut-Based Products by the LC–MS/MS Method
por: Er Demirhan, Buket, et al.
Publicado: (2022)

Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice
por: Campos Polo, Rafael, et al.
Publicado: (2018)

Evolutionary significance of metabolic network properties
por: Basler, Georg, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6l9vufhd7b80fi0glevn73vr1r